Chronic Lymphocytic Leukemia Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Chronic Lymphocytic Leukemia stocks.

Chronic Lymphocytic Leukemia Stocks Recent News

Date Stock Title
Nov 21 TEVA Teva Pharmaceutical (TEVA): The Global Leader in Affordable Medicine Under $25
Nov 20 BIIB Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside
Nov 20 BIIB Biogen Inc. (BIIB): Among the Best Genomics Stocks to Buy Right Now
Nov 19 AFMD Is Affimed N.V. (AFMD) the Best German Stock to Buy Now?
Nov 19 BIIB Biogen, UCB release phase 3 data on lupus candidate dapirolizumab
Nov 19 TEVA Teva Pharmaceutical Industries Limited (TEVA) Jefferies London Healthcare Conference (Transcript)
Nov 19 BIIB Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity
Nov 18 BIIB Biogen's Outlook Dims As Analyst Projects Flat Revenue Until 2026
Nov 18 BIIB Needham downgrades Biogen on slow growth of Alzheimer's drug
Nov 18 BIIB Biogen cut to hold by Needham on lack of catalysts, slow Leqembi sales
Nov 18 BIIB Samsung Bioepis and Biogen Receive European Commission (EC) Approval for Aflibercept Biosimilar, OPUVIZ™
Nov 18 BIIB Is Biogen Inc. (BIIB) A Cheap NASDAQ Stock To Invest In Now?
Nov 17 EBS First mpox case linked to African outbreak reported in U.S.
Nov 16 TEVA Plant-Based API Market Poised To Hit $52 Billion By 2034, Driven By Psychedelics And Cannabinoids
Nov 15 EGRX Eagle Announces Update on Delisting from Nasdaq and SEC Deregistration
Nov 15 GMAB Genmab A/S (GMAB): Among 12 High Growth Large Cap Stocks to Buy Now
Nov 15 EBS Vaccine stocks drop on concerns about RFK Jr. heading HHS (update)
Nov 15 BIIB Biogen Partner Eisai Gets Positive CHMP Nod for Leqembi in Europe
Nov 15 AFMD Affimed NV (AFMD) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges with ...
Chronic Lymphocytic Leukemia

Chronic lymphocytic leukemia (CLL) is a type of cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell). Early on there are typically no symptoms. Later non-painful lymph nodes swelling, feeling tired, fever, or weight loss for no clear reason may occur. Enlargement of the spleen and anemia may also occur. It typically worsens gradually.Risk factors include having a family history of the disease. Exposure to Agent Orange and certain insecticides might also be a risk. CLL results in the buildup of B cell lymphocytes in the bone marrow, lymph nodes, and blood. These cells do not function well and crowd out healthy blood cells. CLL is divided into two main types: those with a mutated IGHV gene and those without. Diagnosis is typically based on blood tests finding high numbers of mature lymphocytes and smudge cells.Management of early disease is generally with watchful waiting. Infections should more readily be treated with antibiotics. In those with significant symptoms, chemotherapy or immunotherapy may be used. The medications fludarabine, cyclophosphamide, and rituximab are typically the initial treatment in those who are otherwise healthy.CLL affected about 904,000 people globally in 2015 and resulted in 60,700 deaths. The disease most commonly occurs in people over the age of 50. Males are affected more often than females. It is much less common in people from Asia. Five-year survival following diagnosis is approximately 83% in the United States. It represents less than 1% of deaths from cancer.

Browse All Tags